BMY Q2 2017 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q2 2017 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$5.1B+5.6% YoY

Gross Profit

$3.8B73.0% margin

Operating Income

$1.5B29.2% margin

Net Income

$916M17.8% margin

EPS (Diluted)

$0.56

QoQ Revenue Growth

+4.4%

Cash Flow

Operating Cash Flow

$1.6B

Free Cash Flow

$1.3B

Stock-Based Comp.

$54M

Balance Sheet

Total Assets

$33.4B

Total Liabilities

$18.6B

Stockholders' Equity

$14.7B

Cash & Equivalents

$3.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.1B	$4.9B	+5.6%
Gross Profit	$3.8B	$3.7B	+2.5%
Operating Income	$1.5B	$1.1B	+32.2%
Net Income	$916M	$1.2B	-21.4%

Revenue Segments

Opdivo

$1.2B23%

Eliquis

$1.2B23%

Orencia

$650M13%

Sprycel

$506M10%

Mature Products And All Other

$479M9%

Yervoy

$322M6%

Baraclude

$273M5%

Reyataz

$188M4%

Sustiva Franchise

$188M4%

Hepatitis C Portfolio

$112M2%

Empliciti

$55M1%